Covidien and Australian firm in novel tracer pact
This article was originally published in Clinica
Executive Summary
Covidien has teamed up with Australian firm NewSouth Innovations to develop a novel tracer that can image dying cells after cancer treatment. The radiolabelled agent could be useful for monitoring treatment in patients with a number of solid tumour cancers. It may also prove valuable in the development of new cancer therapies.